高级检索
当前位置: 首页 > 详情页

Protection by Atorvastatin Pretreatment in Patients Undergoing Primary Percutaneous Coronary Intervention Is Associated With the Lower Levels Of Oxygen Free Radicals

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Capital Med Univ, Beijing Friendship Hosp, Dept Cardiol, Beijing 100050, Peoples R China
出处:
ISSN:

关键词: ischemic reperfusion injury oxygen free radicals atorvastatin

摘要:
Objectives:The aims of this study were to investigate the effects of atorvastatin pretreatment on the oxygen free radicals and its protective role on the myocardial cell during the ischemic reperfusion injury.Methods:One hundred fifty-six patients with ST elevation myocardial infarction undergoing percutaneous coronary interventions, aged from 29 to 85 years, were selected. Eighty patients were randomly assigned to placebo group and 76 to statin treatment (80-mg loading dose given a mean of 1.5 hours before percutaneous coronary intervention). The nitrogen monoxidum, malondialdehyde, and superoxide dismutase (SOD) were assayed before and after reperfusion. Thrombolysis in myocardial infarction (TIMI) grade and corrected TIMI frame count were measured after reperfusion. The creatine kinase-MB and troponin T peak levels after myocardial infarction were recorded.Results:There was no significant difference in the nitrogen monoxidum, malondialdehyde, and SOD levels (P > 0.05) between the 2 groups before intervention. After the reperfusion, significantly lower creatine kinase-MB (289.9 180.8 U/L vs. 360.5 +/- 206.4 U/L, P = 0.025) and troponin T (4.60 +/- 3.13 ng/mL vs. 6.01 +/- 4.98 ng/mL, P = 0.035) peak levels can be observed in the statin versus the placebo group, and the SOD level of the statin group is higher than that of the placebo group (34.14 +/- 15.07 U/mL vs. 29.06 +/- 12.76 U/mL, P = 0.024).Conclusions:Atorvastatin can reduce oxygen free radicals developed in reperfusion, imposing protective effect on the myocardial cell during ischemic reperfusion injury.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2012]版:
大类 | 3 区 医学
小类 | 3 区 心脏和心血管系统 3 区 药学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 心脏和心血管系统 4 区 药学
JCR分区:
出版当年[2011]版:
Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Q2 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Q2 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2011版] 出版当年五年平均[2007-2011] 出版前一年[2010版] 出版后一年[2012版]

第一作者:
第一作者单位: [1]Capital Med Univ, Beijing Friendship Hosp, Dept Cardiol, Beijing 100050, Peoples R China
通讯作者:
通讯机构: [1]Capital Med Univ, Beijing Friendship Hosp, Dept Cardiol, Beijing 100050, Peoples R China [*1]Capital Med Univ, Beijing Friendship Hosp, Dept Cardiol, 59 Yong An Rd, Beijing 100050, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)